Abstract ND09: The discovery and characterization of CFT8634: A potent and selective degrader of BRD9 for the treatment of SMARCB1-perturbed cancers

MLA

Katrina L. Jackson, et al. “Abstract ND09: The Discovery and Characterization of CFT8634: A Potent and Selective Degrader of BRD9 for the Treatment of SMARCB1-Perturbed Cancers.” Cancer Research, vol. 82, June 2022, p. ND09. EBSCOhost, https://doi.org/10.1158/1538-7445.am2022-nd09.

APA

Katrina L. Jackson, Roman V. Agafonov, Mark W. Carlson, Prasoon Chaturvedi, David Cocozziello, Kyle Cole, Richard Deibler, Scott J. Eron, Andrew Good, Ashley A. Hart, Minsheng He, Christina S. Henderson, Hongwei Huang, Marta Isasa, R. Jason Kirby, Linda Lee, Michelle Mahler, Moses Moustakim, Christopher G. Nasveschuk, … Stewart L. Fisher. (2022). Abstract ND09: The discovery and characterization of CFT8634: A potent and selective degrader of BRD9 for the treatment of SMARCB1-perturbed cancers. Cancer Research, 82, ND09. https://doi.org/10.1158/1538-7445.am2022-nd09

Chicago

Katrina L. Jackson, Roman V. Agafonov, Mark W. Carlson, Prasoon Chaturvedi, David Cocozziello, Kyle Cole, Richard Deibler, et al. 2022. “Abstract ND09: The Discovery and Characterization of CFT8634: A Potent and Selective Degrader of BRD9 for the Treatment of SMARCB1-Perturbed Cancers.” Cancer Research 82 (June): ND09. doi:10.1158/1538-7445.am2022-nd09.